Drugs / YE-NEO-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03552718 | Aug 2018 → Mar 2025 | breast cancer, colorectal cancer, head and neck squamous cell carcinoma, liver cancer +3 | NantBioScience, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YE-NEO-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03552718 ↗ |
| Known as | YE-NEO-001 Injectable Suspension | “YE-NEO-001 Injectable Suspension” NCT03552718 ↗ |
| Modality | Vaccine | “personalized neoepitope yeast-based vaccine” NCT03552718 ↗ |